Man Caught Using E-Cigarette with Illegal Substance on Train

Regulations by 2FIRSTS.ai
Jan.04.2024
Man Caught Using E-Cigarette with Illegal Substance on Train
A man was caught using an e-cigarette containing illegal substance on a train in Guangzhou, China.

According to a report by China News Network on January 3, the Guangzhou railway police recently successfully apprehended a man who was using an e-cigarette containing ethyl methylphenidate in the train restroom. The individual has been subjected to administrative penalties as per the law.

 

According to reports, this incident occurred on the Z111 train running between Ganzhou and Shaoguan East. A man was found lying in the restroom by the train police, using an e-cigarette alone. He appeared to be in a dazed state and showed no reaction to the sudden arrival of the police. After being woken up and questioned by the authorities, the man admitted to the fact that the e-cigarette contained the illegal substance ethyl methylamino cyclohexane. The train police then took the man to the police station at Guangzhou Station for further processing.

 

After undergoing urine drug testing, a man named Ma (pseudonym), 21 years old, unemployed, and holder of a standing ticket from Ganzhou to Shaoguan East, was confirmed to have tested positive for methamphetamine in his urine. Furthermore, he fully admitted to his illegal actions. According to Ma's recollection, he engaged in the use of an e-cigarette containing methamphetamine in the bathroom only after his phone became unusable. He also stated that he was well aware that methamphetamine had been officially classified as a narcotic and psychoactive drug, but still succumbed to impulsiveness and tried it a couple of times, ultimately being apprehended by the police. Currently, the Guangzhou Railway Police have lawfully punished Ma and confiscated his e-cigarette device and related items.

 

Since October 1, 2023, the use of methoxyflurane has officially been included in the list of anesthetic and psychotropic drugs. Any illegal activities such as use, smuggling, trafficking, transportation, or manufacturing involving methoxyflurane will be treated as a drug-related crime and prosecuted according to the law.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire and IKE Tech Welcome FDA Enforcement Boost, Highlight Need for Tech-Based Controls
Ispire and IKE Tech Welcome FDA Enforcement Boost, Highlight Need for Tech-Based Controls
Ispire Technology and IKE Tech issued statements after the U.S. FDA received Congressional funding and directives to strengthen enforcement against illicit vaping products. The companies emphasized updated guidance, multi-agency coordination and the role of blockchain and age-verification technologies in preventing illegal imports and protecting youth.
Nov.20
Morocco Aligns Cigarette Pricing Structure with New 2026 Tax Adjustment
Morocco Aligns Cigarette Pricing Structure with New 2026 Tax Adjustment
Morocco will raise retail cigarette prices by 1–2 dirhams (≈ US$ 0.10–0.20) per pack starting January 1, 2026, as part of the final phase of its tobacco tax reform. The adjustment mainly affects value-category cigarette brands; premiums remain largely unchanged.
Dec.01
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.
Nov.26
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
HQD has listed the disposable HQD GO on its official site and U.S. channels. The device touts 35,000 puffs, three power levels with adjustable airflow, and a 30 mg/ml nicotine strength. On U.S. retail websites, it’s priced at about $29.99.
Oct.24 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Russian State Duma Committee supports bill for tobacco and nicotine products market legalization
Russian State Duma Committee supports bill for tobacco and nicotine products market legalization
A bill endorsing a licensing system for tobacco and nicotine products has been recommended in Russia's State Duma.
Nov.14 by 2FIRSTS.ai